Table 1 |
||
|
Cohort characteristics |
||
|
Cases (n = 148) |
Controls (n = 32) |
|
|
|
||
|
Mean age at delivery in years (SD) |
32.3 (3.8) |
32.0 (4.4) |
|
Median disease duration at delivery in years (range) |
8.0 (0.7 to 29.7) |
- |
|
Number of nulliparous women, n (%) |
70/147 (47.6) |
14/32 (43.8%) |
|
Mean gestational age at delivery, weeks (range) |
39.3 (31.4 to 42.1) |
40.4 (34.0 to 42.0) |
|
Breastfeeding (six weeks postpartum), n (%) |
62/148 (41.9) |
27/32 (84.4) |
|
Anti-CCP positive, n (%) |
93/147 (63.3) |
- |
|
Rheumatoid Factor (IgM) positive, n (%) |
108/148 (73.0) |
- |
|
Erosive disease, n (%) |
43/147 (70.7) |
|
|
DAS28-CRP3 >3.2 in first trimester, n (%) |
75 (61.5) |
- |
|
Classification of disease activity during pregnancy |
||
|
good response/moderate response |
37/75 (49.3) |
- |
|
no response |
38/75 (50.7) |
- |
|
Classification of disease activity during postpartum period (early flare) |
||
|
severe deterioration/moderate deterioration (n, %) |
35/141* (24.8) |
- |
|
no deterioration (n, %) |
106/141* (75.2) |
- |
|
Classification of disease activity during postpartum period (late flare) |
||
|
severe deterioration/moderate deterioration (n, %) |
29/141* (20.6) |
- |
|
no deterioration (n, %) |
112/141* (79.4) |
- |
|
Median number of DMARDs (incl prednisone) prior to conceive (min-max) |
2 (0-7) |
- |
|
No DMARD** use prior to conceive, n (%) |
7/147 (4.8) |
|
|
Use of methotrexate prior to conceive, n (%) |
75/147 (51.0) |
- |
|
|
||
|
*n = 7 cases are missing, since a small proportion of DAS scores are missing. ** DMARDs: disease modifying anti-rheumatic drugs. |
||
|
van de Geijn et al. Arthritis Research & Therapy 2009 11:R193 doi:10.1186/ar2892 |
||
